CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 41 enrolled
Drug / intervention
LY3025876 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01528124
NCT01528124Phase 1Completed

A Single-Dose, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of LY3025876 in Healthy Subjects

Eli Lilly and Company·interventional·Posted Feb 7, 2012·Updated Jul 16, 2018

In Brief

A Phase 1 clinical trial evaluating LY3025876 and Placebo for Healthy Volunteers. Completed, enrolled 41 participants across 1 site.

Detailed Summary

This trial is conducted in Singapore. The aim of this trial is to evaluate the safety and tolerability of the study drug in healthy people and investigate how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSingapore
Collaborators--

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 7, 2012
Enrollment StartFeb 1, 2012
Primary CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 14.4 years ago

Interventions

LY3025876drug

Given as a subcutaneous injection

Placebodrug

Given as a subcutaneous injection